Abstract
Risperidone is a second-generation (atypical) antipsychotic drug used worldwide for positive symptoms of schizophrenia mainly. Beside oral and parenteral forms, a long-acting depot formulation as an injection every 4 weeks is also available. As a high-potency antipsychotic acting as D2 receptor antagonist, it tends to produce significant extrapyramidal side effects. The efficacy in treatment of psychoses was established in numerous randomized, double-blind, placebo-controlled studies, and maintenance studies.
Paliperidone, the active metabolite of risperidone, is approved for the short- and long-term treatment of schizophrenia in adults and adolescents as well as for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants. There are some advantages compared to risperidone, so it is recommended in patients with hepatic impairment and evokes less drug-drug interactions. A long-acting depot formulation as an injection every 3 months is also available.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Alphs L, Benson C, Cheshire-Kinney K, Lindenmyer JP, Mao L, Rodriguez SC, et al. Real world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76:554–61.
Bitter I, Katona L, Zambori J, et al. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol. 2013;23:1383–90.
Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind trial. Am J Psychiatry. 1998;155:499–504.
Bouchard RH, Merette C, Pourcher E, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. J Clin Psychopharmacol. 2000;20:295–304.
Chue P, Chue J. A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder. Ther Clin Risk Manag. 2016;12:109–16.
Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the manage-ment of schizophrenia. Drugs. 2010;70:1295–317.
Conley RR. Risperidone side effects. J Clin Psychiatry. 2000;61(Suppl 8):20–3. discussion 24-5
Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R D. 2015;15:163–74.
Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol fort he prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16–22.
de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80–8.
Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm. 2008;65:403–13.
Dove D, Warren Z, McPheeters ML, Taylor JL, et al. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics. 2012;130:717–26.
Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2015;116:315–20.
Glick ID, Correll CU, Altamura AC, Marder SR, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011;72:1616–27.
Hargarter L, Cherubin P, Bergmans P, Keim S, et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2015;58:1–7.
Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs. 2016;30:27–39.
Hiemke C, Bergemann N, Clement HW, Conca A, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–51.
Jarema M, Bieńkowski P, Heitzman J, Parnowski T, Rybakowski J. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia. Psychiatr Pol. 2017;51:7–21.
Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev. 2007:CD005040.
Kim SW, Chung YC, Lee YH, Lee JH, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol. 2012;27:267–74.
Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74:568–75.
Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011:CD006626.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–71.
Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004;65:1084–9.
Mc Evoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311(19):1978–87.
Möller HJ. Risperidone: a review. Expert Opin Pharmacother. 2005;6:803–18.
Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015;41:627–36.
Nivoli AM, Murru A, Goikolea JM, Crespo JM, et al. New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord. 2012;140:125–41.
Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012;6:CD008296.
Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-Centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166:712–26.
Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016;12:CD006918.
Sampson S, Hosalli P, Furtado VA, Davis JM. Risperidone (depot) for schizophrenia. Cochrane Database Syst Rev. 2016;4. Art No: CD004161.
Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Exp Rev Clin Pharmacol. 2018;6:625–39.
Schotte A, Janssen PF, Megens AA, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993;631:191–202.
Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, et al. Paliperidone palmitate vs oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–399.23.
Subotnik KL, Casaus LR, Ventura J, Luo JS, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiat. 2015;72:822–9.
Taipale H, Mittendorf-Rutz E, Majak W, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197.
Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat. 2017;74:686–93.
Voss EA, Ryan PB, Stang PE, Hough D, Alphs L. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Int Clin Psychopharmacol. 2015;30:151–157.29.
Wesołowska A, Jastrzębska-Więsek M, Cios A, Partyka A. The preclinical discovery and development of paliperidone for the treatment of schizophrenia. Exp Opin Drug Discov. 2020;15:279–92.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Laux, G. (2022). Risperidone and Paliperone in the Treatment of Psychosis. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_473
Download citation
DOI: https://doi.org/10.1007/978-3-030-62059-2_473
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-62058-5
Online ISBN: 978-3-030-62059-2
eBook Packages: MedicineReference Module Medicine